- Home
- CIF vs LSTA Comparison
CIF vs LSTA Comparison
Compare CIF & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIF | LSTA |
|---|---|---|
| Founded | 1988 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 20.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CIF | LSTA |
|---|---|---|
| Price | $1.76 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 43.9K | 33.7K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $1.81 |
| 52 Week High | $1.77 | $4.20 |
Technical Indicators
Market Signals| Indicator | CIF | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 40.21 |
| Support Level | $1.68 | $1.85 |
| Resistance Level | $1.75 | $2.09 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 88.89 | 34.41 |
Price Performance
Historical ComparisonAbout CIF MFS Intermediate High Income Fund
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.